CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies / 医学前沿
Frontiers of Medicine
;
(4): 783-804, 2021.
Article
in English
| WPRIM
| ID: wpr-922520
ABSTRACT
The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
T-Lymphocytes
/
Hematologic Neoplasms
/
Receptors, Chimeric Antigen
/
Immunotherapy
/
Neoplasms
Limits:
Humans
Language:
English
Journal:
Frontiers of Medicine
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS